Hiv
Conditions
Keywords
HIV, Extracellular Vesicles
Brief summary
This study aims to evaluate the role of extracellular vesicles in HIV-infection, by determining the expression profile and content of EVs before and after treatment initiation in HIV-infected patients, through extensive blood and tissue sampling (leukapheresis, stool sampling and colon biopsies). A one-time sampling (blood, stool, colon biopsies) will also be performed in HIV-seronegative healthy volunteers to confirm that results found in HIV-infected patients are related to the disease.
Interventions
None listed
Sponsors
University Hospital, Ghent
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
A. HIV-infected individuals A.1. Inclusion Criteria: * Documented untreated HIV-1 infection defined as followed: HIV-1-specific antibody+(western blot); p31+ (ELISA) * CD4 T cell count will be determined standard of care (SOC). A minimum of 16 patients will be included with a CD4 T cell count lower than 350 cells/µl and a minimum of 16 patients with a CD4 T cell count higher than 350 cells/µl * Able and willing to provide written informed consent * Age ≥ 18 years and ≤ 65 years * Ability to attend the complete schedule of assessments and patient visits as described in the schedule below * Ability and willingness to have blood, stool and colon samples collected and stored for 20 years after finalizing the study, and used for various research purposes A.2.
Exclusion criteria
* Recent HIV-infection, early diagnosis * Previous or current history of opportunistic infection (AIDS defining events as defined in category C of the CDC clinical classification), consisting of chronic HIV-1 infection * Evidence of active HBV infection (Hepatitis B surface antigen positive or HBV viral load positive in the past and no evidence of subsequent seroconversion (=HBV antigen or viral load negative and positive HBV surface antibody)) * Evidence of active HCV infection: HCV antibody positive result within 60 days prior to study entry with positive HCV viral load or, if the HCV antibody result is negative, a positive HCV RNA result within 60 days prior to study entry * Current or known history of cardiomyopathy or significant ischemic or cerebrovascular disease * Current or known history of cancer * Pregnancy or breastfeeding * Any conditions, including preexisting psychiatric and psychological disorders, which will in the opinion of the investigator interfere with the trial conduct or safety of the participant. An initial psychiatric assessment will be made by the treating physician. Since making a correct psychological assessment at the time of diagnosis can be difficult, a visit with a psychologist is planned for patients included in the study, for a second evaluation. This will be planned within the first month after diagnosis. In consultation with the psychologist, further sampling will be planned or the patient will be excluded from further sampling. * Previous participation in a trial evaluating an immune modulating agent * Abnormal laboratory tests results at screening: 1. Confirmed hemoglobin \<11g/dl for women and \<12 g/dl for men 2. Confirmed platelet count \< 100 000/µl 3. Confirmed neutrophil count \<1000/μl 4. Confirmed AST and/or ALT \> 10x ULN * Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements * Acute or serious illness, in the opinion of the site investigator, requiring systemic treatment and/or hospitalization within 60 days prior to entry * Known inflammatory bowel disease (Crohn's disease or ulcerative colitis) B. Healthy Volunteers B.1. Inclusion Criteria: * Able and willing to provide written informed consent * Age ≥ 18 years and ≤ 65 years * Ability to attend the complete sampling schedule, as described below * Ability and willingness to have blood, stool and colon samples collected and stored for 20 years and used for various research purposes B.2.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Extracellular Vesicles analysis-NTA | 6 years | Extracellular vesicles (EV) will be isolated through a combination of size-exclusion chromatography (SEC) and Optiprep density gradient (ODG). Nanoparticle Tracking Analysis (NTA) will be performed to obtain the concentration and size distribution of EVs in the samples. |
| Extracellular Vesicles analysis-microscopy | 6 years | The isolated EVs will be further visualized by (electron) microscopy. |
| Extracellular Vesicles analysis-western blot | 6 years | The isolated EVs will be further characterized through western blot. |
| Extracellular Vesicles analysis-PCR | 6 years | The isolated EVs will be further characterized through PCR. |
| Extracellular Vesicles analysis-proteomics | 6 years | The isolated EVs will be further characterized through proteomic analysis. |
| Extracellular Vesicles analysis-RNAsequencing | 6 years | The isolated EVs will be further characterized through RNA sequencing. |
| Extracellular Vesicles analysis-reporter assays | 6 years | Reporter assays will be performed to quantitatively measure bacterial EV-associated lipopolysaccharide (LPS). |
| Quantification of HIV DNA and RNA | 6 years | Digital PCR |
| Immunological analysis-FACS | 6 years | Immunophenotyping by flow cytometric assays will be performed of different cells to assess the phenotype of innate immune cells, using FACS analysis. |
| Immunological analysis-ELISA | 6 years | Immunophenotyping by flow cytometric assays will be performed of different cells to assess the phenotype of innate immune cells, using ELISA. |
| Gene expression analysis/transcriptomics | 6 years | — |
| Microbiome monitoring | 6 years | Gut microbiome will be analyzed in stool and colon biopsies using next-generation sequencing (NGS) of rRNA gene amplicons to identify bacteria at genus/species level |
| Virological analysis-FLIPS | 6 years | HIV will be characterized by Full Length Individual Proviral Sequencing (FLIPS). |
| Virological analysis-integration site | 6 years | HIV will be characterized by integration site analysis. |
Countries
Belgium
Contacts
Primary ContactLinos Vandekerckhove, Prof. Dr.
Outcome results
None listed